Time to refresh thinking on the terminology and management of hypothyroidism? by Leese, Graham & Soto-Pedre, Enrique
                                                                    
University of Dundee
Time to refresh thinking on the terminology and management of hypothyroidism?








Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Leese, G., & Soto-Pedre, E. (2021). Time to refresh thinking on the terminology and management of
hypothyroidism? Clinical Endocrinology. https://doi.org/10.1111/cen.14485
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 24. May. 2021
Clinical Endocrinology. 2021;00:1–2.   | 1wileyonlinelibrary.com/journal/cen
Received: 1 April 2021  | Revised: 12 April 2021  | Accepted: 14 April 2021
DOI: 10.1111/cen.14485  
C O M M E N T A R Y
Time to refresh thinking on the terminology and management 
of hypothyroidism?
Graham Leese1  |   Enrique Soto- Pedre2
1University of Dundee – Endocrinology, Dundee, UK
2University of Dundee – Division of Molecular and Clinical Medicine, Dundee, UK
Correspondence: Graham Leese, University of Dundee – Endocrinology, Ward 5 Ninewells Hospital Dundee DD19SY, UK.
Email: graham.leese2@nhs.scot
Keywords: clinical psychology, Conditions: thyroid, hormones/related: pituitary, hypothyroidism, L- thyroxine, subclinical hypothyroidism, 
thyrotropin
Replacement therapy with L- thyroxine is not universally success-
ful at reversing all symptoms for people with hypothyroidism.1 For 
such patients, current guidelines recommend looking for other 
co- morbidities including hypoadrenalism, celiac disease, anaemia, 
hypercalcaemia, sleep apnoea, renal failure and other conditions. 
If there are ongoing symptoms, recent focus has been on the pos-
sible utility of liothyronine. The timely review by Perros et al1 ar-
gues about thinking beyond this narrow perspective to look at 
broadening potential treatments as well as expanding research 
ideas.
The reviewers (1) explain that somatic symptoms are likely to co- 
exist with common conditions such as hypothyroidism. In the same 
way that people with depression or hypogonadism may benefit from 
a combination of pharmacological and psychological input, such as 
cognitive behavioural therapy, it is argued that some people with 
hypothyroidism may also benefit from such a combined approach. 
Limited access to clinical psychology in many areas should not limit 
our aspirations to offer such care and explore which forms of psy-
chological input may help most. Intriguing early data is presented 
that reducing the “inflammatory” load by thyroidectomy or selenium 
may help adverse symptoms. Further research is required before 
these interventions, metformin2 and other approaches to reduce 
the inflammatory load can be recommended. They also encourage 
us not to neglect the impact of treating depression, improving phys-
ical activity and managing obesity can have on well- being in people 
with hypothyroidism. The authors suggest that using liothyronine is 
ineffective, at least for the vast majority of people with hypothyroid-
ism, as judged by the lack of benefit in meta- analyses of randomized 
controlled trials (RCT).
Although liothyronine may not resolve ongoing adverse symp-
toms in the majority of people with hypothyroidism, it may be pre-
mature to dismiss it altogether. Future RCTs may be better focussing 
on those with persistent adverse symptoms3 rather than anyone 
with hypothyroidism. Also, the interaction between liothyronine use 
and genetic polymorphisms is intriguing although not well charac-
terized.4,5 It is noteworthy that the meta- analyses do not demon-
strate the superiority of L- thyroxine over combined L- thyroxine and 
liothyronine, which throws the focus onto the cost and safety of 
liothyronine. The excessive cost of liothyronine in the UK is being in-
vestigated6 but currently makes it difficult for healthcare providers 
to recommend liothyronine until there is strong evidence of its bene-
fit. Safety data are as yet limited, but do not identify major concerns 
on human data.7,8 The control of tissue liothyronine concentrations 
involving membrane receptor uptake, de- iodination, nuclear thy-
roid receptor binding and other nuclear protein binding is complex.9 
Pharmacological tools to manipulate these processes are currently 
lacking and it is not possible to fine- tune intracellular liothyronine 
concentrations, or its downstream intracellular effects.
We have previously reported that only 62% of patients on L- 
thyroxine have a serum TSH in the reference range10 and others 
report similar data,11 suggesting that current treatment goals with 
L- thyroxine alone are frequently not achieved. This is however cross- 
sectional data. We can report longitudinal data in our local cohort of 
11,335 hypothyroid patients treated only with L- thyroxine. Over a 
mean of 12- year follow- up (range 1– 25 years) with an average 1.25 
TSH tests per year, only 1360 (12%) never had a serum TSH out 
with the reference range (unpublished data). If followed up for 15– 
25 years (mean 19 years), only 4% of 2710 patients always achieved 
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a serum TSH in the reference range. Does this reflect variable drug 
absorption impacted by foods and other interfering medications, 
variable drug delivery, variable concordance, variable metabolism 
and elimination of absorbed thyroxine, or some other issue affecting 
variable serum TSH concentrations? In reality, it may be all these fac-
tors, but it gives plenty of scope to explain and highlights the need 
to explore, some of the adverse symptoms experienced by patients 
on L- thyroxine.
TSH assays are not perfect,12 as there is the potential for assay 
interference, and unexpected results should be interpreted in the 
context of previous and repeated tests. Despite this, TSH assays are 
the best measure adequacy of thyroid replacement that is currently 
available,13 although there may be potential for better tests in the 
future.
Clinicians are starting L- thyroxine10 at increasingly lower concen-
trations of serum TSH.11 Despite guidelines not recommending L- 
thyroxine when people have subclinical hypothyroidism with serum 
TSH between 4 and 10 mU/L and normal free thyroid hormone 
concentrations, treatment is often started in an attempt to improve 
symptoms which were unlikely to be due to thyroid dysfunction. 
This can create unrealistic patient expectation and dissatisfaction 
when starting on a prolonged course of L- thyroxine. It is noteworthy 
that a third of patients previously established on L- thyroxine remain 
biochemically euthyroid when L- thyroxine is stopped.13 This is three 
times more common if the original diagnosis was subclinical hypo-
thyroidism compared with overt hypothyroidism.14 When patients 
with troublesome symptoms have biochemistry results returned and 
the term subclinical disease is used, the question may be raised as to 
whether this really is “sub” clinical. The temptation can be to start 
L- thyroxine to see whether it helps some symptoms even though it 
has been shown that three or more symptoms of hypothyroidism 
are required to have any predictive power of distinguishing hypo-
thyroidism from non- thyroidal illness.15 Perhaps now is the time to 
abandon the term “subclinical hypothyroidism”. In diabetes the term, 
“pre- diabetes” is used to identify patients who are at risk of develop-
ing diabetes but who do not have diabetes mellitus. A term such as 
“pre- thyroid” or “pre- hypothyroid” may be preferable. However, the 
term pre- hypothyroidism still telescopes the “hypothyroid” propen-
sity of the condition. To avoid this issue, the term pre- thyroid could 
be used for what is currently called subclinical hypothyroidism and 
subclinical hyperthyroidism using a grading scheme similar but subtly 
different to that previously proposed.16 People with a normal free T4 
and free T3 could be categorized as pre- thyroid disease grade 1 (TSH 
4– 10 mU/L), grade 2 (TSH > 10mU/L), grade 3 (TSH 0.1– 0.4 mU/L), 
grade 4 (TSH 0.03– 0.1 mU/L) and even grade 5 (TSH < 0.03 mU/L). 
This approach could identify patients with “grade 1 pre- thyroid dis-
ease” who are at risk of thyroid disease but who do not yet have 
thyroid disease and will not benefit from pharmacological treatment, 
but who require ongoing monitoring, and thus creating more realistic 
expectations.
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